BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gruver AM, Peerwani Z, Tubbs RR. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 2010;63:210-9. [PMID: 20203220 DOI: 10.1136/jcp.2009.062760] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Lee Y, Ryu Y, Jeong H, Chang H, Kim Y, Kim A. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study. Arch Med Res 2012;43:139-44. [PMID: 22475781 DOI: 10.1016/j.arcmed.2012.03.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Ching CB, Amin MB, Tubbs RR, Elson P, Platt E, Dreicer R, Fergany A, Hansel DE. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol 2011;24:1111-9. [DOI: 10.1038/modpathol.2011.69] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 6.1] [Reference Citation Analysis]
3 Ohlschlegel C, Kradolfer D, Hell M, Jochum W. Comparison of automated and manual FISH for evaluation of HER2 gene status on breast carcinoma core biopsies. BMC Clin Pathol 2013;13:13. [PMID: 23601823 DOI: 10.1186/1472-6890-13-13] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
4 Portier BP, Gruver AM, Huba MA, Minca EC, Cheah AL, Wang Z, Tubbs RR. From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma. N Biotechnol 2012;29:665-81. [PMID: 22504737 DOI: 10.1016/j.nbt.2012.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Li X, Chew SH, Chay WY, Lim-Tan SK, Goh LK. Optimizing Ventana chromogenic dual in-situ hybridization for mucinous epithelial ovarian cancer. BMC Res Notes 2013;6:562. [PMID: 24373486 DOI: 10.1186/1756-0500-6-562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Koh YW, Lee HJ, Lee JW, Kang J, Gong G. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol. 2011;24:794-800. [PMID: 21317877 DOI: 10.1038/modpathol.2011.9] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
7 Ko JS, Billings SD, Lanigan CP, Buehler D, Fernandez AP, Tubbs RR. Fully automated dual-color dual-hapten silver in situ hybridization staining for MYC amplification: a diagnostic tool for discriminating secondary angiosarcoma: DISH for MYC in angiosarcoma. J Cutan Pathol 2014;41:286-92. [DOI: 10.1111/cup.12278] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
8 Yan B, Choo SN, Mulyadi P, Srivastava S, Ong CW, Yong KJ, Putti T, Salto-Tellez M, Lim GS. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol 2011;64:1097-101. [PMID: 21896578 DOI: 10.1136/jclinpath-2011-200082] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
9 Rovigatti U. Cancer modelling in the NGS era - Part I: Emerging technology and initial modelling. Crit Rev Oncol Hematol 2015;96:274-307. [PMID: 26427785 DOI: 10.1016/j.critrevonc.2015.05.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gray PN, Dunlop CL, Elliott AM. Not All Next Generation Sequencing Diagnostics are Created Equal: Understanding the Nuances of Solid Tumor Assay Design for Somatic Mutation Detection. Cancers (Basel) 2015;7:1313-32. [PMID: 26193321 DOI: 10.3390/cancers7030837] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 5.6] [Reference Citation Analysis]
11 Tsuchiya KD. Fluorescence in situ hybridization. Clin Lab Med 2011;31:525-42, vii-viii. [PMID: 22118735 DOI: 10.1016/j.cll.2011.08.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
12 Zhang W, Hubbard A, Baca-Parkinson L, Stanislaw S, Vladich F, Robida MD, Grille JG, Maxwell D, Tsao TS, Carroll W, Gardner T, Clements J, Singh S, Tang L. Oligonucleotide PIK3CA/Chromosome 3 Dual in Situ Hybridization Automated Assay with Improved Signals, One-Hour Hybridization, and No Use of Blocking DNA. J Mol Diagn 2015;17:496-504. [PMID: 26163898 DOI: 10.1016/j.jmoldx.2015.04.007] [Reference Citation Analysis]
13 Brügmann A, Sorensen BS. Identifying responders to trastuzumab therapy in breast cancer. Future Oncology 2011;7:767-73. [DOI: 10.2217/fon.11.44] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Moelans CB, de Weger RA, Van der Wall E, van Diest PJ. Current technologies for HER2 testing in breast cancer. Crit Rev Oncol Hematol 2011;80:380-92. [PMID: 21273092 DOI: 10.1016/j.critrevonc.2010.12.005] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 6.8] [Reference Citation Analysis]
15 Lim SJ, Cantillep A, Carpenter PM. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization. Hum Pathol 2013;44:2590-6. [PMID: 24075600 DOI: 10.1016/j.humpath.2013.07.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
16 Yan B, Yau EX, Choo SN, Ong CW, Yong KJ, Pang B, Salto-Tellez M. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples. J Clin Pathol. 2011;64:880-883. [PMID: 21757431 DOI: 10.1136/jclinpath-2011-200009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
17 Mentrikoski MJ, Stoler MH. HER2 immunohistochemistry significantly overestimates HER2 amplification in uterine papillary serous carcinomas. Am J Surg Pathol 2014;38:844-51. [PMID: 24698965 DOI: 10.1097/PAS.0000000000000182] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
18 Mendez P, Ramirez JL. Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung. Transl Lung Cancer Res 2013;2:101-11. [PMID: 25806221 DOI: 10.3978/j.issn.2218-6751.2013.03.05] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Franchet C, Filleron T, Cayre A, Mounié E, Penault-Llorca F, Jacquemier J, Macgrogan G, Arnould L, Lacroix-Triki M. Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study. Histopathology 2014;64:274-83. [PMID: 24117939 DOI: 10.1111/his.12247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
20 Foged NT, Brügmann A, Jørgensen JT. The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment. Expert Rev Mol Diagn 2013;13:233-42. [PMID: 23570400 DOI: 10.1586/erm.13.6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
21 Sanguedolce F, Bufo P. HER2 assessment by silver in situ hybridization: where are we now? Expert Rev Mol Diagn 2015;15:385-98. [PMID: 25578771 DOI: 10.1586/14737159.2015.992416] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
22 Hwang CC, Pintye M, Chang LC, Chen HY, Yeh KY, Chein HP, Lee N, Chen JR. Dual-colour chromogenic in-situ hybridization is a potential alternative to fluorescence in-situ hybridization in HER2 testing. Histopathology 2011;59:984-92. [PMID: 22092410 DOI: 10.1111/j.1365-2559.2011.04037.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
23 Warford A. In situ hybridisation: Technologies and their application to understanding disease. Prog Histochem Cytochem 2016;50:37-48. [PMID: 26797255 DOI: 10.1016/j.proghi.2015.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
24 Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, Rakha EA. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. Br J Cancer 2019;120:1075-82. [PMID: 31065110 DOI: 10.1038/s41416-019-0436-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
25 Galea LA, Newman M, Au RS, Leong TY, Williams DS. Development of a silver in situ hybridisation based assay for the determination of ploidy status in molar pregnancy diagnosis. Pathology 2014;46:15-20. [PMID: 24300715 DOI: 10.1097/PAT.0000000000000025] [Reference Citation Analysis]
26 Tsuda H, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. BMC Cancer. 2010;10:534. [PMID: 20925963 DOI: 10.1186/1471-2407-10-534] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
27 Chen JR, Hsieh TY, Chen HY, Yeh KY, Chen KS, ChangChien YC, Pintye M, Chang LC, Hwang CC, Chien HP. Absence of estrogen receptor alpha gene (ESR1) gene amplification in a series of breast cancers in Taiwan. Virchows Arch. 2014;464:689-699. [PMID: 24756215 DOI: 10.1007/s00428-014-1576-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]